Drugs / Canvaxin
Canvaxin
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT00128583 | Jul 2005 → ? | cutaneous melanoma | CancerVax Corporation | Unknown | No outcome recorded |
| Phase 31 trial · 1 missed | ||||||
| Phase 3 | NCT00052156 | — | melanoma | CancerVax Corporation | Unknown | Missed primary |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CANVAXIN | “Response of In-Transit Melanoma to Systemic Treatment With the Specific Active Immunotherapeutic Agent, Canvaxin™” NCT00128583 ↗ |
| Known as | CancerVax vaccine | “CancerVax vaccine (CANVAXIN)” NCT00052156 ↗ |
| Known as | polyvalent melanoma vaccine | “Patients receive polyvalent melanoma vaccine (Canvaxin™) subcutaneously to the armpit and groin areas every 2 weeks for approximately 10 weeks (5 doses) and then every 4 weeks...” NCT00128583 ↗ |
| Modality | Vaccine | “allogeneic whole-cell vaccine (Canvaxin™)” PMID 29019177 ↗ Oct 2017 |
| Route | Subcutaneous | “Patients receive polyvalent melanoma vaccine (Canvaxin™) subcutaneously to the armpit and groin areas every 2 weeks for approximately 10 weeks (5 doses) and then every 4 weeks...” NCT00128583 ↗ |